DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 115 filers reported holding DENALI THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $22,703 | -42.1% | 450 | -10.0% | 0.00% | -50.0% |
| Q2 2021 | $39,220 | +37.4% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $28,550 | -31.8% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $41,880 | +133.8% | 500 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $17,915 | +48.2% | 500 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $12,090 | +38.1% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $8,755 | +0.5% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $8,710 | +13.7% | 500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $7,660 | -48.4% | 500 | -30.1% | 0.00% | 0.0% |
| Q2 2019 | $14,843 | -10.6% | 715 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $16,602 | +703.6% | 715 | +615.0% | 0.00% | – |
| Q4 2018 | $2,066 | -5.0% | 100 | 0.0% | 0.00% | – |
| Q3 2018 | $2,174 | +42.6% | 100 | 0.0% | 0.00% | – |
| Q2 2018 | $1,525 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |